This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.
October 15th 2019
analyst reports
October 15th 2019
press releases
October 10th 2019
press releases
October 10th 2019
press releases
This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.
September 26th 2019
analyst reports
September 26th 2019
press releases
Upcoming Events
Whats next.
October 15th 2019 - October 17th 2019
read more
November 6th 2019 - November 10th 2019
read more
passion.
It takes a great deal of passion on the fight against cancer. We put our heart and soul into winning it.
know-how.
Our goal is to gather the strongest forces, the brightest minds and the most dedicated employees.
research.
Accurate research is the strong foundation for developing potential in effective treatment.
What is LAG3?
Lymphocyte-activation gene 3, or LAG-3 (LAG3), is a cell surface molecule with biologic effects on T cell function.
LAG3 is being used for many cancer immunotherapy treatments including Eftilagimod Alpha from Immutep.
